The Manufacturers Life Insurance Company raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 3.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,221 shares of the biopharmaceutical company’s stock after purchasing an additional 1,175 shares during the quarter. The Manufacturers Life Insurance Company owned 0.06% of Theravance Biopharma worth $1,244,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of TBPH. BlackRock Inc. grew its stake in Theravance Biopharma by 117,412.4% during the 1st quarter. BlackRock Inc. now owns 3,512,445 shares of the biopharmaceutical company’s stock valued at $129,326,000 after purchasing an additional 3,509,456 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Theravance Biopharma by 341.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 256,110 shares of the biopharmaceutical company’s stock valued at $9,430,000 after purchasing an additional 198,062 shares in the last quarter. Vanguard Group Inc. grew its stake in Theravance Biopharma by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 3,080,296 shares of the biopharmaceutical company’s stock valued at $113,417,000 after purchasing an additional 125,223 shares in the last quarter. Wells Fargo & Company MN grew its stake in Theravance Biopharma by 174.8% during the 2nd quarter. Wells Fargo & Company MN now owns 88,688 shares of the biopharmaceutical company’s stock valued at $3,533,000 after purchasing an additional 56,418 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new stake in Theravance Biopharma during the 2nd quarter valued at approximately $1,915,000. Hedge funds and other institutional investors own 84.54% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Theravance Biopharma, Inc. (TBPH) Holdings Raised by The Manufacturers Life Insurance Company” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/11/theravance-biopharma-inc-tbph-holdings-raised-by-the-manufacturers-life-insurance-company.html.

TBPH has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, October 25th. Robert W. Baird restated a “sell” rating and set a $22.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Finally, BidaskClub lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Four analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Theravance Biopharma has an average rating of “Hold” and a consensus price target of $41.86.

In other news, EVP Bradford J. Shafer sold 14,670 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total value of $451,395.90. Following the completion of the transaction, the executive vice president now owns 134,327 shares in the company, valued at approximately $4,133,241.79. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Frank Pasqualone bought 4,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was purchased at an average price of $26.34 per share, with a total value of $105,360.00. Following the transaction, the senior vice president now owns 213,180 shares in the company, valued at approximately $5,615,161.20. The disclosure for this purchase can be found here. 6.10% of the stock is currently owned by company insiders.

Theravance Biopharma, Inc. (TBPH) opened at $28.77 on Friday. The company has a current ratio of 7.53, a quick ratio of 6.53 and a debt-to-equity ratio of 1.21. Theravance Biopharma, Inc. has a 12-month low of $23.15 and a 12-month high of $43.44.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.